Dr Hamburg is Obama

23 March 2009

Dr Hamburg is Obama's FDA Commissioner pick

US President Barack Obama has nominated Margaret Hamburg, the Health  Commissioner for New York City, to be the next permanent Food and Drug  Administration Commissioner, replacing Frank Torti, who has held the  position on an acting basis since the New Year. Dr Hamburg's main areas  of expertise are considered to be food safety and bioterrorism and the  President's remarks in a radio interview about the appointment indicate  that contaminated food scandals are a major element of the new  Commissioner's remit.

There were effusive messages of support from the Biotechnology Industry  Organization and the Pharmaceutical Research and Manufacturers of  America (PhRMA), with the latter "applauding" the President on "his  expeditious selection," not mentioning that this may have been delayed  by the fiasco surrounding the nomination of the Secretary of the  Department of Health and Human Services (Marketletters passim). The  Generic Pharmaceutical Association, which would seem to have rather more  cause to be pleased with the new administration, issued a more measured  statement, opening with a quote from its president, Kathleen Jaeger, who  said: "GPhA stands ready to work with Dr Margaret Hamburg on the  critical issues facing the agency as it carries out its mission to  protect the public health."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight